<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lace B</submitter><funding>Eesti Teadusagentuur</funding><funding>King Salman Center for Disability Research</funding><funding>National Institutes of Health</funding><funding>National Science Board</funding><funding>European Regional Development Fund</funding><pagination>297-304</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11558465</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>65(5)</volume><pubmed_abstract>The &lt;i>PTCD3&lt;/i> gene product (protein PTCD3 or MRPS39) forms the entry channel of the mitochondrial small ribosomal subunit and binds to single-stranded mRNA. Here, we expand on the clinical manifestations of &lt;i>PTCD3&lt;/i> pathogenic variants by describing an early-onset patient with Leigh-like syndrome and two patients with milder form of disease, with combined oxidative phosphorylation deficiency. A 34-year-old male and his 33-year-old sister both have horizontal nystagmus, pronounced rough tremor, truncal ataxia, dysmetria, spasticity and hyperreflexia. The basal respiration rate decreased significantly for the male patient and his mother (&lt;i>p&lt;/i> &lt; 0.0001) compared to the controls. The whole genome sequencing analysis revealed two heterozygous variants in the &lt;i>PTCD3&lt;/i>: c.1182T>A, </pubmed_abstract><journal>JIMD reports</journal><pubmed_title>The phenotypic spectrum of &lt;i>PTCD3&lt;/i> deficiency.</pubmed_title><pmcid>PMC11558465</pmcid><funding_grant_id>R15GM148890</funding_grant_id><funding_grant_id>PSG774</funding_grant_id><funding_grant_id>MCB‐2024182</funding_grant_id><funding_grant_id>KSRG‐2022‐105</funding_grant_id><funding_grant_id>KSCDR‐RAC: 2180 004</funding_grant_id><funding_grant_id>1.1.1.1/18/A/096</funding_grant_id><pubmed_authors>Kaya N</pubmed_authors><pubmed_authors>Wright NT</pubmed_authors><pubmed_authors>Mayr JA</pubmed_authors><pubmed_authors>Micule I</pubmed_authors><pubmed_authors>Lace B</pubmed_authors><pubmed_authors>Faqeih E</pubmed_authors><pubmed_authors>Krumina Z</pubmed_authors><pubmed_authors>Achleitner MT</pubmed_authors><pubmed_authors>Pajusalu S</pubmed_authors><pubmed_authors>Stavusis J</pubmed_authors><pubmed_authors>AlQudairy H</pubmed_authors><pubmed_authors>Zayakin P</pubmed_authors><pubmed_authors>Inashkina I</pubmed_authors></additional><is_claimable>false</is_claimable><name>The phenotypic spectrum of &lt;i>PTCD3&lt;/i> deficiency.</name><description>The &lt;i>PTCD3&lt;/i> gene product (protein PTCD3 or MRPS39) forms the entry channel of the mitochondrial small ribosomal subunit and binds to single-stranded mRNA. Here, we expand on the clinical manifestations of &lt;i>PTCD3&lt;/i> pathogenic variants by describing an early-onset patient with Leigh-like syndrome and two patients with milder form of disease, with combined oxidative phosphorylation deficiency. A 34-year-old male and his 33-year-old sister both have horizontal nystagmus, pronounced rough tremor, truncal ataxia, dysmetria, spasticity and hyperreflexia. The basal respiration rate decreased significantly for the male patient and his mother (&lt;i>p&lt;/i> &lt; 0.0001) compared to the controls. The whole genome sequencing analysis revealed two heterozygous variants in the &lt;i>PTCD3&lt;/i>: c.1182T>A, </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2026-06-02T10:38:59.272Z</modification><creation>2025-04-04T00:21:59.106Z</creation></dates><accession>S-EPMC11558465</accession><cross_references><pubmed>39544688</pubmed><doi>10.1002/jmd2.12424</doi></cross_references></HashMap>